NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $2.25 -0.07 (-3.02%) Closing price 04/4/2025 03:51 PM EasternExtended Trading$2.11 -0.14 (-6.22%) As of 04/4/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evoke Pharma Stock (NASDAQ:EVOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evoke Pharma alerts:Sign Up Key Stats Today's Range$2.19▼$2.3450-Day Range$2.25▼$5.4052-Week Range$2.19▼$12.32Volume21,280 shsAverage Volume120,842 shsMarket Capitalization$3.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More… Remove Ads Evoke Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreEVOK MarketRank™: Evoke Pharma scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Evoke Pharma. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evoke Pharma is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evoke Pharma is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evoke Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.48% of the float of Evoke Pharma has been sold short.Short Interest Ratio / Days to CoverEvoke Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evoke Pharma has recently decreased by 32.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvoke Pharma does not currently pay a dividend.Dividend GrowthEvoke Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.48% of the float of Evoke Pharma has been sold short.Short Interest Ratio / Days to CoverEvoke Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evoke Pharma has recently decreased by 32.69%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News SentimentN/A News SentimentEvoke Pharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Evoke Pharma this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evoke Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $180.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evoke Pharma is held by insiders.Read more about Evoke Pharma's insider trading history. Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Stock News HeadlinesShort Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7%April 1, 2025 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.comMarch 29, 2025 | americanbankingnews.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 5, 2025 | American Alternative (Ad)Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?March 28, 2025 | americanbankingnews.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 16, 2025 | uk.finance.yahoo.comEarnings call transcript: Evoke Pharma Q4 2024 reports strong sales growthMarch 15, 2025 | uk.investing.comQ4 2024 Evoke Pharma Inc Earnings CallMarch 14, 2025 | finance.yahoo.comEvoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comSee More Headlines EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $4.42 at the start of the year. Since then, EVOK stock has decreased by 49.1% and is now trading at $2.25. View the best growth stocks for 2025 here. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) posted its earnings results on Thursday, March, 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.24. The specialty pharmaceutical company had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative trailing twelve-month return on equity of 308.49%. When did Evoke Pharma's stock split? Evoke Pharma shares reverse split before market open on Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings3/13/2025Today4/05/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVOK CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-71.32% Pretax Margin-71.32% Return on Equity-308.49% Return on Assets-53.66% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.39 Sales & Book Value Annual Sales$10.25 million Price / Sales0.33 Cash FlowN/A Price / Cash FlowN/A Book Value($9.26) per share Price / Book-0.24Miscellaneous Outstanding Shares1,493,000Free Float1,395,000Market Cap$3.36 million OptionableNot Optionable Beta0.30 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:EVOK) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.